Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Positive Malignant Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03368729
What this trial is testing

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2 Positive Breast Carcinoma
University of Alabama at Birmingham 46
Not applicableUnknownNCT03655353
What this trial is testing

68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Henrik Lindman 160
Not applicableUnknownNCT05169853
What this trial is testing

Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerHER2-positive Breast Cancer
Ain Shams University 80
Not applicableLooking for participantsNCT06035016
What this trial is testing

Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer

Who this might be right for
HER2-positive Breast CancerEarly-stage Breast Cancer
Peking Union Medical College Hospital 300
Large-scale testing (Phase 3)Active Not RecruitingNCT06747338
What this trial is testing

A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer

Who this might be right for
Early or Locally Advanced HER2-positive Breast Cancer
Shanghai JMT-Bio Inc. 520
Testing effectiveness (Phase 2)WithdrawnNCT04273555
What this trial is testing

Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging

Who this might be right for
HER2-positive Breast Cancer
University of Alabama at Birmingham
Testing effectiveness (Phase 2)Study completedNCT04072952
What this trial is testing

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Arvinas Estrogen Receptor, Inc. 217
Early research (Phase 1)Active Not RecruitingNCT04704661
What this trial is testing

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Who this might be right for
Advanced Breast CarcinomaAdvanced Colon CarcinomaAdvanced Colorectal Carcinoma+37 more
National Cancer Institute (NCI) 51
Not applicableStudy completedNCT01564368
What this trial is testing

DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy

Who this might be right for
Breast Cancer
American College of Radiology Imaging Network 406
Not applicableStudy completedNCT02286362
What this trial is testing

An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 510
Testing effectiveness (Phase 2)Active Not RecruitingNCT05593094
What this trial is testing

Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsHER2-positive Breast Cancer
Hoffmann-La Roche 210
Large-scale testing (Phase 3)UnknownNCT05346861
What this trial is testing

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

Who this might be right for
HER2-positive Breast CancerMetastatic Breast Cancer
Fudan University 240
Testing effectiveness (Phase 2)Looking for participantsNCT07708194
What this trial is testing

Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure

Who this might be right for
Breast CancerHER2-positive Breast CancerHormone Receptor-Positive Breast Cancer+1 more
Tianjin Medical University Cancer Institute and Hospital 94
Large-scale testing (Phase 3)Study completedNCT03705429
What this trial is testing

A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer

Who this might be right for
Breast Neoplasms
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's 51
Testing effectiveness (Phase 2)WithdrawnNCT01361945
What this trial is testing

AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerHER-2 Positive Breast Cancer+1 more
Texas Tech University Health Sciences Center, El Paso
Not applicableActive Not RecruitingNCT03460067
What this trial is testing

Omission of Radiation in Patients With Her-2 Positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
University of Kansas Medical Center 12
Very early researchStudy completedNCT04267900
What this trial is testing

99mTc-HPArk2 SPECT/CT for the Detection of HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
Peking Union Medical College Hospital 34
Testing effectiveness (Phase 2)Active Not RecruitingNCT03379428
What this trial is testing

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Who this might be right for
Breast NeoplasmsMalignant Neoplasm of Breast
US Oncology Research 34
Not applicableStudy completedNCT07829900
What this trial is testing

First-Line Dual Versus Single HER2-Targeted Therapy With Docetaxel for Advanced HER2-Positive Breast Cancer

Who this might be right for
HER2-Positive Breast CancerAdvanced Breast Cancer
Xin Li 2,250
Testing effectiveness (Phase 2)Study completedNCT01565200
What this trial is testing

HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1

Who this might be right for
HER-2 Positive Breast Cancer
Jules Bordet Institute 90
Next Page